|
US2019298758A1
|
|
Antimetastatic 2H-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents
|
|
CA2988391A1
|
|
Substituted aminoalkylazoles as malarial aspartic protease inhibitors
|
|
EP3127539A1
|
|
Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
|
|
WO2016159747A1
|
|
Ethynylxanthines, preparation and use as calcium ion channel modulators
|
|
GB2553684A
|
|
Ethynylxanthines, preparation and use for cancer treatment
|
|
GB2553685A
|
|
Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis
|
|
WO2015063543A1
|
|
Hydridopalladium(ii) halides as preformed catalysts for suzuki-miyaura cross-coupling reactions
|
|
WO2015063544A1
|
|
Novel substituted 2-aminoquinazolin-4(3h)-one derivatives as malarial aspartic protease inhibitors
|
|
GEP201706747B
|
|
Pharmaceutical composition for reducing the trimethylamine n-oxide level
|
|
CA2910514A1
|
|
Thieno[2,3-.beta.]pyridines as multidrug resistance modulators
|
|
TWI324927B
|
|
Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium
|
